Doctor profile · Federal record
Dr. Haresh Jhangiani, M.D.
Specialist (CMS: Hematology/Oncology) · Fountain Valley, CA
- NPI 1578566998
- Accepts Medicare
- 48 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
11180 Warner Ave, Ste 351
Fountain Valley, CA 927087516
(714) 698-0300
fax (714) 698-0302
Credentials & registration
- NPI registered
- May 2005 — 21 yrs on file
- Profile last updated
- March 8, 2019
- Year of graduation
- 1978 — 48 yrs since
- Specialty taxonomy
- 174400000X — NUCC code
- State license (1)
- California #A38872
- Medicaid
- CA #00A388720
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1578566998. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
2,975
Distinct HCPCS
8
Medicare allowed
$155,214
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0897 |
Injection, denosumab, 1 mg | 1,860 | 11 | $23 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 553 | 143 | $137 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 156 | 20 | $150 | |
J3489 |
Injection, zoledronic acid, 1 mg | 148 | 19 | $9 | |
96367 |
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 109 | 11 | $33 | |
96372 |
Injection of drug or substance under skin or into muscle | 84 | 23 | $16 | |
96365 |
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | 22 | $73 | |
99215 |
Established patient office or other outpatient visit, 40-54 minutes | 18 | 13 | $193 |
In context: peer comparison
Among 8 peers in this city , average services per provider: 359. This provider delivers 8.3× the peer median.Open Payments
Industry payments received
All-time total
$12,456
Transactions
226
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Gilead Sciences, Inc. | 20 | $5,554.72 | |
| Janssen Biotech, Inc. | 24 | $765.31 | |
| Merck Sharp & Dohme LLC | 17 | $516.24 | |
| AstraZeneca Pharmaceuticals LP | 21 | $508.58 | |
| Novartis Pharmaceuticals Corporation | 18 | $481.77 | |
| Alexion Pharmaceuticals, Inc. | 13 | $442.35 | |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $350.52 | |
| Eisai Inc. | 14 | $309.34 | |
| Celgene Corporation | 22 | $306.91 | |
| PUMA BIOTECHNOLOGY, INC. | 10 | $262.83 | |
| Exelixis Inc. | 9 | $229.09 | |
| GlaxoSmithKline, LLC. | 12 | $217.49 | |
| ABBVIE INC. | 13 | $211.69 | |
| PFIZER INC. | 13 | $204.40 | |
| BeiGene USA, Inc. | 8 | $190.08 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
311
Patients
38
Total drug cost
$1,137,253
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 76 | 27 | $2,312 |
| Dexamethasone Sodium Phosphate | Generic | 27 | 0 | $165 |
| Levothyroxine Sodium | Generic | 25 | 0 | $508 |
| Gabapentin | Generic | 19 | 11 | $272 |
| Revlimid (Lenalidomide) | Brand | 19 | 0 | $363,571 |
| Ondansetron Hcl (Ondansetron Hcl/Pf) | Brand | 18 | 0 | $67 |
| Fosaprepitant Dimeglumine | Generic | 16 | 0 | $4,037 |
| Jakafi (Ruxolitinib Phosphate) | Brand | 16 | 0 | $294,182 |
| Lenalidomide | Generic | 14 | 0 | $174,961 |
| Sodium Chloride (0.9 % Sodium Chloride) | Brand | 14 | 0 | $158 |
Hospital affiliations
Frequently asked questions
What is Dr. Haresh Jhangiani's medical specialty?
Dr. Haresh Jhangiani practices Specialist in Fountain Valley, CA.
Where does Dr. Haresh Jhangiani practice?
Dr. Haresh Jhangiani practices at 11180 Warner Ave, Fountain Valley, CA 927087516. Office phone: 7146980300.
What is Dr. Haresh Jhangiani's NPI?
Dr. Haresh Jhangiani's National Provider Identifier (NPI) is 1578566998, issued by NPPES.
Does Dr. Haresh Jhangiani accept Medicare assignment?
Yes. Dr. Haresh Jhangiani accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Haresh Jhangiani commonly perform?
Top Medicare-reported procedures in 2023: Injection, denosumab, 1 mg (HCPCS J0897); Established patient office or other outpatient visit (HCPCS 99214); Administration of chemotherapy into vein (HCPCS 96413). Source: CMS Medicare Physician & Other Practitioners file.